Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




2011 BIO International Convention Sets Attendance Records

By LabMedica International staff writers
Posted on 06 Jul 2011
The 2011 BIO International Convention, the largest global event for the biotechnology industry, set new records in partnering meetings, and increased international attendance and participation. More...
The convention program included panel sessions on the latest scientific, policy and business opportunities and challenges facing the industry. The conference, hosted by the Biotechnology Industry Organization (BIO; Washington DC, USA) in Washington DC (USA), drew 15,626 industry leaders from the US and other 65 countries.

“The 2011 BIO International Convention was an enormous success, bringing together leaders from industry, government, and academia who are working to solve some of the sector’s biggest challenges,” said President and CEO of BIO Jim Greenwood. “Bringing the global biotech industry to Washington DC, [USA], gave us the critical opportunity to showcase to key policymakers our industry’s promise to offer real solutions to the most pressing global challenges such as curing disease, reducing health care costs, combating hunger, discovering alternative forms of energy and creating high-wage jobs. We continue to advocate for a policy and regulatory environment that will support innovation and inspire industry growth.”

Keynote sessions included the former UK Prime Minister Tony Blair, US Senator John Barrasso, former US Senator Tom Daschle, Vermont Governor Howard Dean, and Republican political strategist Karl Rove. The Convention program featured more than 125 sessions across 15 tracks, including Global Innovations and Markets, Health Policy and Reimbursement, Biosecurity, Business Development, Food and Agriculture, and Biofuels, and Biobased Chemicals.

The BIO Business Forum hosted a record-breaking 21,183 partnering meetings between 2,410 companies and featured 157 company presentations. According to the BIO Business Forum Partnering Report there is high demand for Phase I assets as well as Central Nervous System (CNS), immunology, and metabolic therapeutic areas compared to 2010. In addition, the 2010 top-three-highest interest therapeutic areas in including cardiovascular, oncology, and respiratory categories are now all in the bottom half of 2011's top 10 areas.

The 2012 BIO International Convention will take place during June 18-21, 2012, at the Boston Convention and Exhibition Center in Boston (MA, USA).

Related Links:
BIO International Convention
Biotechnology Industry Association



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.